Skip Navigation Skip to main content
  • Warning Signs
  • Volunteer
  • Donate
return to American Heart Association Newsroom
  • Heart Attack And Stroke Symptoms
  • Volunteer
  • Donate
Newsroom
    • News Media Embargoed Access
    • Login to Password Protected Newsroom
    • Apply for Embargoed Access
    • Embargo Policy and Guidelines
    • American Heart Association Fact Sheets
    • Boilerplates
    • Copyright Permissions
    • Glossary of Scientific Terms
    • Linking Policy
    • Scientific Statements/Guidelines
    • Scientific Publications: Purposes-Processes
    • Statistics
    • Multimedia Resources
    • Animation/Video
    • Images/Graphics
    • Audio
    • Usage Policy
    • Connect With Us
    • Media Contacts
    • Consumer/Media Connections
  • Twitter
  • Facebook
  • YouTube
  • RSS
  • Email Alerts
  1. Newsroom
  2. Search News Releases
  3. Study finds trend toward benefit in using blood-clotting agent for bleeding stroke
Categories: Stroke News & Brain Health, Scientific Conferences & Meetings
|
Published: February 21, 2020

Study finds trend toward benefit in using blood-clotting agent for bleeding stroke

American Stroke Association International Stroke Conference – Late Breaking Science News Release (LB 20)
facebook Facebook
twitter Twitter
facebook LinkedIn
facebook Email
facebook Print

Related Images

Previous Slide Next Slide

Nawaf Yassi, M.B.B.S., presents LB 20

Nawaf Yassi, M.B.B.S., presents the Spot Sign and Tranexamic Acid on Preventing ICH Growth - Australasia Trial (STOP-AUST): A Multicenter, Randomized, Double-blind, Placebo-controlled Trial during ME III, Closing Main Event at the American Heart Association / American Stroke Association International Stroke Conference at the Los Angeles Convention Center.

copyright American Heart Association -Photo by Todd Buchanan 2020

Download (1.8 MB)
Nawaf Yassi, M.B.B.S., presents LB 20

Nawaf Yassi, M.B.B.S., presents LB 20

Nawaf Yassi, M.B.B.S., presents the Spot Sign and Tranexamic Acid on Preventing ICH Growth - Australasia Trial (STOP-AUST): A Multicenter, Randomized, Double-blind, Placebo-controlled Trial during ME III, Closing Main Event at the American Heart Association / American Stroke Association International Stroke Conference at the Los Angeles Convention Center.

copyright American Heart Association -Photo by Todd Buchanan 2020


Please see AHA/ASA Multimedia Materials Usage Policy.

Download (1.8 MB) File Permalink

Nawaf Yassi, M.B.B.S., B.Sc., Ph.D.

Nawaf Yassi, M.B.B.S., B.Sc., Ph.D., neurologist, Royal Melbourne Hospital, Melbourne, Australia

copyright Joss Dimock

Download (131.0 kB)
Nawaf Yassi, M.B.B.S., B.Sc., Ph.D.

Nawaf Yassi, M.B.B.S., B.Sc., Ph.D.

Nawaf Yassi, M.B.B.S., B.Sc., Ph.D., neurologist, Royal Melbourne Hospital, Melbourne, Australia

copyright Joss Dimock


Please see AHA/ASA Multimedia Materials Usage Policy.

Download (131.0 kB) File Permalink

ISC Logo

copyright American Stroke Association

Download (62.9 kB)
ISC Logo

ISC Logo

copyright American Stroke Association


Please see AHA/ASA Multimedia Materials Usage Policy.

Download (62.9 kB) File Permalink
  • Nawaf Yassi, M.B.B.S., presents LB 20
  • Nawaf Yassi, M.B.B.S., B.Sc., Ph.D.
  • ISC Logo

Related Video

Previous Slide Next Slide

Elkind ISC20 perspective on LB 20

Mitchell S. V. Elkind, M.D., M.S., FAHA, FAAN, president elect of the American Heart Association, past chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association and professor of neurology and epidemiology at Columbia University New York and attending neurologist at Columbia University Medical Center of the New York-Presbyterian Hospital.

Transcript (txt)

News Release

copyright American Heart Association

Download (294.4 MB)
Sorry, your browser doesn\'t support embedded videos, download and watch with your favorite video player!

Elkind ISC20 perspective on LB 20

Mitchell S. V. Elkind, M.D., M.S., FAHA, FAAN, president elect of the American Heart Association, past chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association and professor of neurology and epidemiology at Columbia University New York and attending neurologist at Columbia University Medical Center of the New York-Presbyterian Hospital.

Transcript (txt)

News Release

copyright American Heart Association


Please see AHA/ASA Multimedia Materials Usage Policy.

Download (294.4 MB) File Permalink

Elkind ISC20 on LB 20 tranexamic Acid

Mitchell S. V. Elkind, M.D., M.S., FAHA, FAAN, president elect of the American Heart Association, past chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association and professor of neurology and epidemiology at Columbia University New York and attending neurologist at Columbia University Medical Center of the New York-Presbyterian Hospital.

Transcript (txt)

News Release

copyright American Heart Association

Download (119.5 MB)
Sorry, your browser doesn\'t support embedded videos, download and watch with your favorite video player!

Elkind ISC20 on LB 20 tranexamic Acid

Mitchell S. V. Elkind, M.D., M.S., FAHA, FAAN, president elect of the American Heart Association, past chair of the Advisory Committee of the American Stroke Association — a division of the American Heart Association and professor of neurology and epidemiology at Columbia University New York and attending neurologist at Columbia University Medical Center of the New York-Presbyterian Hospital.

Transcript (txt)

News Release

copyright American Heart Association


Please see AHA/ASA Multimedia Materials Usage Policy.

Download (119.5 MB) File Permalink
  • Elkind ISC20 perspective on LB 20
  • Elkind ISC20 on LB 20 tranexamic Acid
AHA Logo
This link is provided for convenience only and is not an endorsement of either the linked-to entity or any product or service.
CLOSE PROCEED